Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Michel Seymour(University of Leeds), Richard Stephens(Keele University), Angela Meade(Medical Research Council), Anthony Maraveyas(University of Hull), Jonathan A. Ledermann(London Cancer), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Tim Maughan(University of Liverpool), David Ferry(Eli Lilly (United States)), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), Stephen J. Gwyther(East Surrey Hospital), Stephen F Shepherd(Cheltenham General Hospital), C. Topham, Mahesh Parmar(University College London), R.D. James(University of Kent), Lindsay C Thompson(MRC Clinical Trials Unit at UCL)
Cited by 570
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k